The Vibrant Immunochip is made from recombinant proteins of several species of Borrelia burgdorferi, and not just from B31 used by other western blot tests. Vibrant criteria for detection has higher sensitivity and specificity than the two-tier testing by CDC criteria, as demonstrated by internal studies. This eliminates doubt for clinicians.
The Vibrant Tickborne Diseases panel is the first of its kind to be run on a silicon micro-array platform, providing the highest level of specificity and sensitivity in the industry for detecting tickborne diseases.
Patients often present with a range of non-specific symptoms that may be Lyme, or other conditions that have symptom overlap. Patients with diagnosed Lyme may also experience resurgence of symptoms, which might suggest co-infections. Co-infections are complex and should be included in an initial screen of Lyme and related illnesses.
Vibrant has the most comprehensive antibody (indirect) and DNA (direct) test for detection of Lyme and co-infections that, in most cases, can assist the clinician in assessing these situations and lead to the correct diagnosis.
Because standard treatment for tickborne diseases usually involves courses of antibiotics that are prolonged, this can also leave the patient at risk for multiple chronic inflammatory symptoms or conditions due to impact to the microbiome. It is recommended that patients being treated for tickborne diseases undergo regular microbiome screening during antibiotic therapy, such as the Vibrant Gut Zoomer or Vibrant Gut Pathogens tests.